Teva Pharmaceutical Industries Ltd., Indivor PLC, and Viatris Inc dominated the Global Medication-Assisted Treatment (MAT) Market in 2021

The Global Medication-Assisted Treatment (MAT) Market is expected to grow with a CAGR of 9.4% in the forecast period of 2022 to 2029. The years considered for the study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-medication-assisted-treatment-mat-market

The global medication-assisted treatment (MAT) market is highly fragmented market and has a number of key players. The market has witnessed increased strategic developments owing to a favourable market scenario.

The major players dealing in the global medication-assisted treatment (MAT) market are introducing a strong range of products launching new products, and adopting strategic initiatives such as acquisition, agreement, business expansion, awards and recognition in the market. This helped companies to maximize sales with an enhanced product portfolio.

For instance:

  • In April 2022, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth and ZIMHI being made available at a discounted rate for first responders and community health organizations

Teva Pharmaceutical Industries Ltd is the dominating player in the global medication-assisted treatment (MAT) market. The other key players existing in the market are Indivior PLC, Orexo US Inc (a subsidiary of Orexo AB), Recovery Centers of America, Alkermes. Sun Pharmaceutical Industries Ltd., Purdue Pharma L.P., Taj Pharmaceuticals Limited, Lannett, Hikma Pharmaceuticals PLC, Pfizer Inc., Pinnacle Treatment Center, American Addiction Centers, Adamis Pharmaceuticals Corporation, Glenmark Pharmaceutical Inc. Viatris Inc., Mallinckrodt, Alvogen, Accord Healthcare, VistaPharm, Inc., Dr. Reddy’s Laboratories Ltd. Amneal Pharmaceuticals LLC. Titan Pharmaceuticals, Inc. among others.

Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd. is headquartered in Tel Aviv-Yafo, Israel, and was founded in 1994. The company is focused in research and development of generic medicines and biopharmaceuticals, carrying on the legacy of more than a century of finding new ways to help patients improve their lives. The various product categories of the company include generic medicines, specialty therapeutic areas, biopharmaceuticals, teva API, quality products, over the counter (OTC) treatments, in which generic medicines is the market focused category.

For instance:

  • In March 2022, Teva Pharmaceutical Industries Ltd.,entered into an agreement with Attorney General (AG) of Rhode Island. The agreement stated, Teva Pharmaceutical Industries Ltd.,would provide naloxone hydrochloride nasal spray) and buprenorphine naloxone (sublingual tablets) branded as Suboxone over a period of ten years., to the U.S., amounting to USD 78.5 million. It Iis expected to increase the supply and revenue sales of buprenoprohine and saloxone and would increase the market growth.

The company has a wide presence across Americas, Europe, Africa, Asia, and Oceania. In addition, the company also generates its revenue from various subsidiaries, including Ratiopharm (Germany), Pliva (Croatia), Cephalon (U.S.), Merckle GmbH (Germany), Mepha (Switzerland), among others.

Indivior PLC

Indivior PLC is headquartered in Virginia, the U.S., and was founded in 1994. The company is focused to help change patients' lives by pioneering life-transforming treatment for substance use disorders and other serious mental illnesses. The various product categories of the company include prescription medicines which is also a market-focused category.

For instance,

  • In April 2022, Indivior PLC, launched SUBLOCADE (buprenorphine-extended release) Injection, at the American Society of Addiction Medicine (ASAM) 2022 Annual Meeting. The launch is expected to increase the business product range across the U.S. and Europe and would increase the revenue

The company has a presence across North America, Europe, and Australia. In addition, the company also generates its revenue from various subsidiaries, including RBP Global Holdings Limited (the U.K.), Indivior Finance LLC (the U.S.), Indivior Finance (2014) LLC (the U.K.), Indivior UK Limited (the U.K.) and AntiOp, Inc. (the U.K.) among others.

Medication-Assisted Treatment (MAT) Market

Viatris Inc.

Viatris Inc. is headquartered in Pennsylvania, U.S, founded in 2020. The company is focused on delivery of increased access to affordable, quality medicines for patients worldwide, regardless of geography or circumstance. The various product categories of the company include brands, generics, biosimilars, over-the-counter products, active pharmaceutical ingredients of which brands, generics is the market focused category.

For Instance,

  • In August 2021, Viatris Inc. launched a generic, combination product of buprenorphine and naloxone (generic Suboxone) – which is indicated for the treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. The launch had expanded the product segment and increased the revenue.

The company has a presence across Americas, Europe, Asia-Pacific and Middle East & Africa. In addition, the company also generates its revenue from various subsidiaries Rottapharm | Madaus GmbH (Germany), MEDA Pharma GmbH and Co. KG (Germany), Merck Generics Belgium B.V.B.A. (Belgium), Arcana Arzneimittel GmbH (Germany), Mylan Laboratories India Private Ltd (India) among others.